Related Experiment Videos
Fibrin D-dimer in thrombogenic disorders
T Matsuo1, H Kobayashi, K Kario
1Hyogo Prefectural Awaji Hospital, Sumoto, Japan.
Seminars in Thrombosis and Hemostasis
|May 11, 2000
Summary
D-dimer testing is crucial for assessing hypercoagulable states and fibrinolysis. Discrepancies in D-dimer measurements between methods were observed in acute conditions, but not in chronic ones.
Area of Science:
- Biochemistry
- Hematology
- Clinical Chemistry
Background:
- D-dimer, a fibrin degradation product, indicates fibrinolysis activation and hypercoagulable state severity.
- Fibrin degradation product variability and antibody reactivity affect D-dimer assay accuracy.
- Discrepancies in D-dimer detection methods are noted in acute fibrinolysis conditions.
Purpose of the Study:
- To investigate discrepancies in D-dimer measurement methods.
- To evaluate D-dimer detection in various clinical settings.
- To assess the utility of D-dimer measurement in hypercoagulable states.
Main Methods:
- Comparison of automated latex agglutination assay (LPIA) and enzyme-linked immunosorbent assay (Stago) for D-dimer detection.
- Analysis of D-dimer levels in patients with acute and chronic conditions.
- Assessment of fibrin formation and degradation markers.
Main Results:
- Discrepancies between LPIA and Stago were found in patients with disseminated intravascular coagulation, stress, and post-angioplasty.
- No significant discrepancies were observed in healthy elderly, lacunar stroke, and coronary artery disease patients.
- Evidence of increased intravascular coagulation and fibrin turnover in atherosclerotic disease patients was found.
Conclusions:
- D-dimer measurement utility depends on the clinical context and assay method.
- High-molecular-weight D-dimer fragments may predict further fibrin degradation.
- LPIA is a suitable marker for ongoing fibrinolysis when intermediate degradation products are assessed.